RNAi Dispute Resolved
In 2005, Oxford Biomedica exclusively licensed the technology to Sigma-Aldrich for commercialization for the research market. LentiVector technology is used to deliver shRNA-encoding RNA to cells for RNAi.
St. Louis, MO 3/7/08—Sigma-Aldrich and Oxford Biomedica have settled their patent litigation against Open Biosystems (see IBO 6/15/06). Under the confidential settlement, Open Biosystems will acquire certain license rights for use of Oxford BioMedica’s LentiVector gene delivery technology in research activities. Other details were not disclosed.
< Previous Article | Next Article >

